The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLI.a

Pulmonary edema, noncardiogenic (NCPE)

Publications

Alsakti AM, Ghazwi ZHA, AlOtaibi AK, Alharbi MA, Aldeaiji LA, Binshmilan AB, Alanazi NMM, Alsharif RE, Aldehaim FM, Alhindi BA, Alodhaib NA, Saleh A, Altamimi A

Clazosentan in aneurysmal subarachnoid hemorrhage: an updated systematic review and meta-analysis of efficacy and safety.

BMC neurology 2026 Jun 11;26; — 2026 Jun 11

Okumura E, Nakaya K, Otsuka K, Jimbo H

Treatment Outcomes of Clazosentan Use During the Perioperative Period for Subarachnoid Hemorrhage.

Cureus 2025 Feb;17;e79497 — 2025 Feb — e79497

Ayabe F, Kino T, Kinoshita T, Sawada K, Saigusa K

Successful administration of clazosentan in subarachnoid hemorrhage patient with severe heart failure.

Surgical neurology international 2024;15;306 — 2024 — 306

Kinoshita H, Kato K, Yamazaki Y, Hashiba E, Hirota K

Successful Fluid Management in Respiratory Failure due to Clazosentan Following a Cerebral Aneurysm Clipping: A Case Report.

Cureus 2024 Feb;16;e54850 — 2024 Feb — e54850